Statins and postmenopausal breast cancer risk; results from the KARMA cohort

他汀类药物与绝经后乳腺癌风险:来自KARMA队列研究的结果

阅读:2

Abstract

PURPOSE: To study the incidence and subtype of breast cancer in relation to incident and prevalent statin use in a contemporary Swedish prospective cohort, The Karolinska Mammography Project for Risk Prediction of Breast Cancer, KARMA. METHODS: A total of 35,315 postmenopausal women attending mammography and included in the KARMA cohort (Jan 2011-March 2013) with data on statin use and potential confounders were studied. During eight years of follow-up, 785 incident invasive breast cancer cases were identified. RESULTS: A total of 16% of women were prevalent statin users (prior to study inclusion) and 9% were incident statin users (following study inclusion). In multivariable Cox regression analyses, there was no significant association between incident or prevalent statin use and risk of incident breast cancer (HR(adj) 1.24, 95% CI 0.89-1.72, and HR(adj) 0.90, 95% CI 0.73-1.11, respectively). Similarly, no significant association was found for incident or prevalent statin use and subtype-specific risk of breast cancer. CONCLUSION: This prospective population-based study performed in a modern screening population with a substantial number of statin users, concurs with previous publications showing no evidence of an association between statin use and risk of postmenopausal breast cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。